Friday 23 September, 2022

14.30 - 15.00 hrs        

Personalis Satellite Symposium

 

Maik Pruess PhD
Senior Field Application Scientist

Personalis, Inc.

​

Personalis NeXT Platform
Enabling the future of precision oncology with comprehensive, unprecedented tumor profiling solutions for both tissue and liquid biopsy

• Combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXT™ provides a multidimensional view of the tumor and the tumor microenvironment from a single tumor sample preparation

• A clinical case study in a cohort of late-stage melanoma patients demonstrating how the integration of neoantigen burden, HLA LOH, and Antigen Presentation Machinery (APM) mutational data formed a composite biomarker that more accurately predicted response to checkpoint blockade than other markers

• In parallel, specimens may be processed using NeXT Personal™, an ultrasensitive tumor-informed liquid biopsy assay, designed to detect molecular residual disease and cancer recurrence at the earliest timepoints, with simultaneous variant tracking for additional insight into disease progression